Big Money Flies with Cardinal Health

And the medical products distributor could rise more due to hefty sales, share repurchase plans, and a healthy dividend. But another likely reason is Big Money lifting the stock.

Cardinal Attracts Big Money

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And Cardinal has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, have a look at the Big Money signals CAH has made over the last year.

The last few weeks have seen Big Money activity too. Each green bar signals big trading volumes as the stock ramped in price:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

In the last year, the stock attracted 19 Big Money buy signals. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out the technical action grabbing my attention:

Outperformance is important for leading stocks.

Cardinal Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, Cardinal has had double-digit sales growth and a favorable earnings outlook. Take a look:

  • 1-year sales growth rate (+11.6%)
  • 1-year EPS growth estimate (+17.3%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, CAH has been a top-rated stock at my research firm, MAPsignals, for years. That means the stock has had buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

CAH has a lot of qualities that are attracting Big Money. It’s made the Top 20 report 57 times since 1993, with its first appearance on 10/18/1993…and gaining 1,286.3% since. The blue bars below show when Cardinal was a top pick:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

It’s been a top stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if CAH makes additional appearances in the years to come. Let’s tie this all together.

Cardinal Price Prediction

The Cardinal rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside, plus it pays a current dividend of 2.8%. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no positions in CAH at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

Big Money Likes ShockWave Medical

And the medical device maker focused on novel angioplasty alternatives could rise more due to strong financial performance and future guidance. But another likely reason is Big Money lifting the stock.

ShockWave Medical Attracts Big Money

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And ShockWave Medical has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, have a look at all the Big Money signals SWAV has made recently.

The last few weeks have seen Big Money activity. Each green bar signals big trading volumes as the stock ra1mped in price:

Chart, histogram

Description automatically generated

Source: www.mapsignals.com

The stock has attracted three Big Money buy signals since August 2022. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out the technical action grabbing my attention:

Outperformance is important for leading stocks.

ShockWave Medical Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, ShockWave Medical has had triple-digit sales growth and a solid future earnings outlook. Take a look:

  • 1-year sales growth rate (+249.8%)
  • 3-year sales growth rate (+185.9%)
  • 2-year vs. 1-year EPS growth estimate (+37.7%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, SWAV has become a top-rated stock at my research firm, MAPsignals. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

SWAV has a lot of qualities that are attracting Big Money. It just made the Top 20 report, with its first appearance on 08/16/2022…and gaining 2.5% since. Big Money may have found a new gem. The blue bar below shows when ShockWave Medical was a top pick:

Chart, histogram

Description automatically generated

Source: www.mapsignals.com

It’s been a growing stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if SWAV makes additional appearances in the years to come. Let’s tie this all together.

ShockWave Medical Price Prediction

The ShockWave Medical rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no positions in SWAV at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

 

SIGA Treats Big Money Well

And the maker of infection disease treatments, including the first U.S. monkeypox treatment, could rise more due to strong sales and profits. But another likely reason is Big Money lifting the stock.

Big Money Seeks SIGA

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And SIGA has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, have a look at all the Big Money signals SIGA has made recently.

The last few weeks have seen Big Money activity. Each green bar signals big trading volumes as the stock ramped in price:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

The stock has attracted seven Big Money buy signals since May 2022. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out the technical action grabbing my attention:

Outperformance is important for leading stocks.

SIGA Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, SIGA has had double-digit sales growth and strong profits. Take a look:

  • 3-year sales growth rate (+93.3%)
  • Profit margin (+52.0%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, SIGA has become a top-rated stock at my research firm, MAPsignals. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

SIGA has a lot of qualities that are attracting Big Money. It just made the Top 20 report, with its first appearance on 05/24/2022…and gaining 170.5% since. Big Money may have found a new gem. The blue bars below show when SIGA was a top pick:

Source: www.mapsignals.com

It’s been a growing stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if SIGA makes additional appearances in the years to come. Let’s tie this all together.

SIGA Price Prediction

The SIGA rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no positions in SIGA at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

Big Money Flocks to Catalyst

And the maker of treatments for rare chronic neuromuscular and neurological diseases could jump more due to its leadership position for some medicines. But another likely reason is Big Money lifting the stock.

Catalyst Attracts Big Money

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And Catalyst has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, have a look at all the Big Money signals CPRX has made recently.

The last few weeks have seen Big Money activity. Each green bar signals big trading volumes as the stock ramped in price:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

In the last month, the stock has attracted four Big Money buy signals. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out the technical action grabbing my attention:

Outperformance is important for leading stocks.

Catalyst Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, Catalyst has had huge sales growth and is growing earnings well too. Take a look:

  • 3-year sales growth rate (+6,798.6%)
  • 3-year EPS growth rate (+43.3%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, CPRX has become a top-rated stock at my research firm, MAPsignals. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

CPRX has a lot of qualities that are attracting Big Money. It just made the Top 20 report, with its first appearance on 08/02/2022…and gaining 2.7% since. Big Money may have found a new gem. The blue bar below shows when Catalyst was a top pick:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

It’s been a growing stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if CPRX makes additional appearances in the years to come. Let’s tie this all together.

Catalyst Price Prediction

The Catalyst rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no positions in CPRX at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

Lantheus Treats Big Money Well

And the maker of medical imaging tools could jump more due to market share gains related to new prostate cancer imaging products. But another likely reason is Big Money lifting the stock.

Big Money Loves Lantheus

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And Lantheus has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, have a look at all the Big Money signals LNTH has made the last year.

The last few weeks have seen Big Money activity too. Each green bar signals big trading volumes as the stock ramped in price:

Source: www.mapsignals.com

So far in 2022, the stock has attracted 18 Big Money buy signals. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out the technical action grabbing my attention:

Outperformance is important for leading stocks.

Lantheus Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, Lantheus has been growing sales well and is expected to grow earnings in the future. Take a look:

  • 1-year sales growth rate (+25.3%)
  • 2-year vs. 1-year EPS growth estimate (+19.3%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, LNTH has become a top-rated stock at my research firm, MAPsignals. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

LNTH has a lot of qualities that are attracting Big Money. It’s made the Top 20 report twice this year, with its first appearance on 05/03/2022…and gaining 16.9% since. The blue bars below show when Lantheus was a top pick:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

It’s been a top stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if LNTH makes additional appearances in the years to come. Let’s tie this all together.

Lantheus Price Prediction

The Lantheus rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no positions in LNTH at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

Incyte Brings in Big Money

And the biopharmaceuticals company could soar higher due to recent regulatory approvals on new cancer and skin treatments. But another likely reason is Big Money lifting the stock.

Big Money Flocks to Incyte

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And Incyte has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, have a look at all the Big Money signals INCY has made the last year.

The last few weeks have seen Big Money activity too. Each green bar signals big trading volumes as the stock ramped in price:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

In the last year, the stock attracted 11 Big Money buy signals. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out the technical action grabbing my attention:

Outperformance is important for leading stocks.

Incyte Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, Incyte has been growing earnings well and sports a healthy profit margin. Take a look:

  • 3-year EPS growth rate (+67.3%)
  • Profit margin (+31.8%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, INCY has been a top-rated stock at my research firm, MAPsignals, for years. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

INCY has a lot of qualities that are attracting Big Money. It’s made the Top 20 report 17 times since 2011, with its first appearance on 07/17/2012…and gaining 216.2% since. It’s beaten down a bit but is still a Big Money favorite. The blue bars below show when Incyte was a top pick:

Chart, histogram Description automatically generated Source: www.mapsignals.com

It’s been a top stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if INCY makes additional appearances in the years to come. Let’s tie this all together.

Incyte Price Prediction

The Incyte rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no positions in INCY at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

Big Money Flocks to Syndax Pharmaceuticals

And the cancer-focused biopharmaceutical company could rise even higher due to a lucrative licensing deal pointing towards big sales gains. But another likely reason is Big Money lifting the stock.

Syndax Pharmaceuticals Attracts Big Money

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And Syndax Pharmaceuticals has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, have a look at all the Big Money signals SNDX has made the last year.

The last few weeks have seen Big Money activity too. Each green bar signals big trading volumes as the stock ramped in price:

Source: www.mapsignals.com

In the last year, the stock attracted eight Big Money buy signals. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out technical action grabbing my attention:

Outperformance is important for leading stocks.

Syndax Pharmaceuticals Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, Syndax Pharmaceuticals has been growing sales at quadruple-digit rates and has an attractive profit margin. Take a look:

  • 3-year sales growth rate (+3,036.5%)
  • Profit margin (+17.8%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, SNDX has become a top-rated stock at my research firm, MAPsignals. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

SNDX has a lot of qualities that are attracting Big Money. It made the Top 20 report for the first time since it began trading in 2016, with its initial appearance on 07/12/2022…and gaining 11.7% since. Big Money may have a new long-term gem on its hands. The blue bar below shows when Syndax Pharmaceuticals was a top pick:

Chart Description automatically generated

Source: www.mapsignals.com

It’s been a top stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if SNDX makes additional appearances in the years to come. Let’s tie this all together.

Syndax Pharmaceuticals Price Prediction

The Syndax Pharmaceuticals rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no positions in SNDX at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

AMN Healthcare Services Attracts Big Money

And the health care staffing company could soar more due to its ability to plug critical health care holes due to personnel shortages. But another likely reason is Big Money lifting the stock.

Big Money Likes AMN Healthcare Services

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And AMN Healthcare Services has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, have a look at all the Big Money signals AMN has made the last year.

The last few weeks have seen Big Money activity too. Each green bar signals big trading volumes as the stock ramped in price:

Source: www.mapsignals.com

In the last year, the stock attracted four Big Money buy signals. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out the technical action grabbing my attention:

Outperformance is important for leading stocks.

AMN Healthcare Services Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, AMN Healthcare Services has been growing earnings and sales well. Take a look:

  • 3-year EPS growth rate (+101.1%)
  • 3-year sales growth rate (+26.1%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, AMN has been a top-rated stock at my research firm, MAPsignals. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

AMN has a lot of qualities that are attracting Big Money. It’s made the Top 20 report four times since 2016, with its first appearance on 04/17/2018…and gaining 69.6% since. The blue bars below show when AMN Healthcare Services was a top pick:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

It’s been a top stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if AMN makes additional appearances in the years to come. Let’s tie this all together.

AMN Healthcare Services Price Prediction

The AMN Healthcare Services rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no positions in AMN at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

Big Money Flocks to Qiagen

Qiagen N.V. (QGEN) stock has jumped the last month, gaining 5.6%. And the Dutch scientific diagnostic company could soar more due to global growth and its bullish outlook. But another likely reason is Big Money lifting the stock.

Qiagen Brings in Big Money

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And Qiagen has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, have a look at all the Big Money signals QGEN has made the last year.

It’s been down a bit, but the last few weeks have seen a flurry of Big Money activity. Each green bar signals big trading volumes as the stock ramped in price:

Chart Description automatically generated

Source: www.mapsignals.com

In the last year, the stock attracted seven Big Money buy signals. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out the technical action grabbing my attention:

Outperformance is important for leading stocks.

Qiagen Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, Qiagen has been growing sales well and sports a healthy profit margin. Take a look:

  • 1-year sales growth rate (+20.4%)
  • Profit margin (+22.8%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, QGEN has been a top-rated stock at my research firm, MAPsignals, for years. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

QGEN has a lot of qualities that are attracting Big Money. It’s made the Top 20 report four times since 2011, with its first appearance on 05/09/2011…and gaining 115.8% since. The blue bars below show when Qiagen was a top pick:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

It’s been a top stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if QGEN makes additional appearances in the years to come. Let’s tie this all together.

Qiagen Price Prediction

The Qiagen rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no positions in QGEN at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

Big Money Returns to Veeva Systems

And the cloud software provider focused on the life sciences industry could rise even more due to strong growth and healthy profits. But another likely reason is Big Money lifting the stock.

Veeva Systems Attracts Big Money

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And Veeva Systems has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, check out how the last few weeks have seen Big Money activity. It’s been a long slide down, but there may be a turnaround ahead. The green bar signals big trading volumes as the stock ramped in price:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

In the last year, the stock attracted a new Big Money buy signal, after receiving them regularly for years. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out technical action grabbing my attention:

Outperformance is important for leading stocks.

Veeva Systems Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, Veeva Systems has been growing sales and earnings at double-digit rates, while also owning a strong profit margin. Take a look:

  • 3-year sales growth rate (+29.0%)
  • 3-year EPS growth rate (+20.7%)
  • Profit margin (+23.1%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, VEEV has been a top-rated stock at my research firm, MAPsignals, for years. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

VEEV has a lot of qualities that are attracting Big Money. It’s made the Top 20 report 45 times since 2015, with its first appearance on 11/01/2015…and gaining 640.4% since. Big Money was all over the shares years ago and it’s recently come back in; the blue bars below show when Veeva Systems was a top pick:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

It’s been a top stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if VEEV makes additional appearances in the years to come. Let’s tie this all together.

Veeva Systems Price Prediction

The Veeva Systems rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no positions in VEEV at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

Big Money Loves Corcept

And the biotechnology company could jump more due to multiple successful drug trials. But another likely reason is Big Money lifting the stock.

Corcept Attracts Big Money

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And Corcept has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, have a look at all the Big Money signals CORT has made the last year.

The last few weeks have seen Big Money activity too. Each green bar signals big trading volumes as the stock ramped in price:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

In the last year, the stock attracted 14 Big Money buy signals. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out technical action grabbing my attention:

Outperformance is important for leading stocks.

Corcept Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, Corcept has been growing earnings well and sports a healthy profit margin. Take a look:

  • 3-year EPS growth rate (+14.5%)
  • Profit margin (+30.7%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, CORT has been a top-rated stock at my research firm, MAPsignals, for years. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

CORT has a lot of qualities that are attracting Big Money. It’s made the Top 20 report 27 times since 2016, with its first appearance on 03/14/2017…and gaining 178.4% since. The blue bars below show when Corcept was a top pick:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

It’s been a top stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if CORT makes additional appearances in the years to come. Let’s tie this all together.

Corcept Price Prediction

The Corcept rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds long positions in CORT in personal and managed accounts at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

Humana Covered with Big Money

And the health insurer could jump more due to strong financial performance and growing demand. But another likely reason is Big Money lifting the stock.

Big Money Likes Humana

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And Humana has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, have a look at all the Big Money signals HUM has made the last year.

The last few weeks have seen Big Money activity too. Each green bar signals big trading volumes as the stock ramped in price:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

In the last year, the stock attracted eight Big Money buy signals. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out technical action grabbing my attention:

Outperformance is important for leading stocks.

Humana Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, Humana has been growing sales and earnings at double digit rates. Take a look:

  • 3-year sales growth rate (+13.8%)
  • 3-year EPS growth rate (+26.9%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, HUM has been a top-rated stock at my research firm, MAPsignals, for years. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

HUM has a lot of qualities that are attracting Big Money. It’s made the Top 20 report 30 times since 1990, with its first appearance on 03/25/1991…and gaining 999.9% since. The blue bars below show when Humana was a top pick:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

It’s been a top stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if HUM makes additional appearances in the years to come. Let’s tie this all together.

Humana Price Prediction

The Humana rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside, plus it pays a nearly 0.7% current dividend yield. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no positions in HUM at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

Best ETFs to Buy Now for July 2022

Everyone was pummeled by inflation and now we have talks of a recession, which usually don’t bode well for markets.

So, how is Big Money reacting? It’s selling more than buying. Let me explain.

Markets and Big Money in the Last Six Months

My research firm, MAPsignals, measures Big Money investor activity. That includes institutions, pension funds, big individual investors, and so on. We follow Big Money because our research shows Big Money moves markets.

We created the Big Money Index (BMI), which is a 25-day moving average of large-scale investor buy and sell activity. Over time it has shown itself to be a leading indicator of where markets may go. The BMI went oversold in May, which is a hugely bullish long-term signal. It’s bounced back a bit since but is trending lower again of late:

Chart, histogram Description automatically generated

The Big Money selling includes shedding the sector that’s been a lone 2022 bright spot – energy. That’s ushered in more volatility as uncertainty continues to reign over inflation, recession, and geopolitical tensions. Check out the recent dip:

Chart, histogram Description automatically generated

On a more macro level, Big Money has been selling ETFs heavily over the past six months. Worse, buying has been basically nonexistent since March, meaning there’s no leadership now. Big selling combined with no buying will drive markets downward every time.

Chart, histogram Description automatically generated

But in times of uncertainty, bargains can be had. This month’s ETF picks have long-term value appreciation in mind. Some of them are experiencing low liquidity right now due to market volatility and a lack of overall leadership. Still, we think these ETFs have great long-term potential: FFTY, IEIH, XLV, FXU, and XLP.

Long-term investors should look for ETFs (and their stocks), with great setups. Remember, ETFs are just baskets of stocks, so we need to look at them in detail. MAPsignals specializes in scoring more than 6,500 stocks daily. If I know which stocks compose the ETFs, I can apply stock scores to the ETFs. Then I can rank them all from strongest to weakest.

Now, let’s get to the best ETFs to buy now for July 2022.

Innovator IBD 50 ETF (FFTY) Analysis

This ETF is a weekly, rules-based, computer-generated stock index with a nearly 1.4% current dividend that seeks to identify the current top 50 growth stocks. It’s seen a downtrend for a while, with no Big Money buying. But, as markets rise again (and they almost certainly will at some point), FFTY should benefit because it holds great stocks focused on growth. It’s down 41.4% so far this year and is trading at an attractive price relative to its peak:

Chart, histogram Description automatically generated

FFTY holds many growth-oriented stocks across different industries. One health care example is Vertex Pharmaceuticals Incorporated (VRTX), which has three-year sales growth of 36.1%, three-year EPS growth of 23.5%, and a 30.8% profit margin. Here is the one-year Big Money action for VRTX:

Chart, histogram Description automatically generated

iShares Evolved U.S. Innovative Healthcare ETF (IEIH) Analysis

This is another low-liquidity ETF, so expect some volatility. That said, IEIH holds tremendous stocks in U.S. pharmaceutical and biotechnology firms with lots of long-term potential and pays a nearly 1.3% current dividend. It’s been choppy for much of the last year, but overall is down just 4.6% so far in 2022:

Chart, histogram Description automatically generated

One great stock IEIH holds is AbbVie, Inc. (ABBV). This drugmaker has seen big three-year EPS growth of 44.3% and sports a profit margin of 20.4%. Sales have been strong too, growing 20.6% over three years. The Big Money has been all over ABBV:

Chart, histogram Description automatically generated

Health Care Select Sector SPDR ETF (XLV) Analysis

Again sticking with the health care sector, XLV holds many great companies across several health care fields, including medicines, insurance, equipment suppliers, and more. This ETF is giant, so there should be no liquidity issues, and pays a more than 1.4% current dividend. XLV has seen Big Money action throughout the past year and is up 0.6% in that time:

Chart, histogram Description automatically generated

A fantastic stock within XLV is Thermo Fisher Scientific Inc. (TMO), a supplier of scientific equipment and services worldwide. It’s down in 2022, but its fundamentals remain strong. TMO has growing sales (one-year sales growth of 21.7%) and three-year EPS growth of 40.8%. Since 2012, TMO has attracted lots of Big Money. Each blue bar below shows when it was a Top 20 Big Money buy:

Chart, histogram Description automatically generated

First Trust Utilities AlphaDEX Fund (FXU) Analysis

When investors seek safety, that often means utilities that pay dividends. That makes sense because we all have to pay our utility bills, recession or not. FXU is a medium-liquidity ETF, so it still experiences some choppiness. But it’s up 5.4% over the past year, pays a more than 2.2% current dividend, and looks to have a bright future:

Chart, histogram Description automatically generated

One rock-solid dividend stock within this ETF is Duke Energy Corporation (DUK), a U.S. energy firm serving southern and midwestern areas of the country. While Big Money has been in and out of it over the past year, DUK has three-year EPS growth of 51.9% and a profit margin of 15.5%. Plus, it jumped 7.2% over a year’s time:

Chart, histogram Description automatically generated

Consumer Staples Select Sector SPDR ETF (XLP) Analysis

With recession fears high, consumer staples stocks are attractive to investors. That’s certainly justified right now. XLP holds several household names consumers buy regularly, is highly liquid, and offers a nearly 2.4% current dividend yield. It’s seen 12 Big Money buy signals in the last year and is up 4.2% in that time:

Chart, histogram Description automatically generated

A great stock in XLP is Coca-Cola Company (KO), the beverage maker (and Warren Buffett favorite). KO is fundamentally strong – it has one-year sales growth of 17.2% and a profit margin of 25.2%. It’s up more than 7% so far in 2022 and it wouldn’t surprise me to see this one rise more (it’s had 48 Top 20 Big Money buy signals since 1992 and is up 1,148.7% in that time):

Chart, histogram Description automatically generated

Here’s a Big Money recap:

  • When Big Money buying heats up, stocks and ETFs tend to rise
  • Deep selling on great quality can be a phenomenal opportunity
  • Repeated buying usually means outsized gains

Bottom Line and Explanatory Video

FFTY, IEIH, XLV, FXU, and XLP are my top ETFs for July 2022. They hover around health care a lot, but also cover other sectors that could rise over time. These picks can climb higher, in my opinion, largely because they each hold great stocks. With markets rocky, bargains can be had, and these ETFs show great long-term potential right now.

To learn more about MAPsignals’ Big Money process please visit: www.mapsignals.com

Disclosure: the author holds no positions in FFTY, IEIH, XLV, FXU, XLP, VRTX, TMO, DUK, or KO at the time of publication, but holds long positions in ABBV in managed accounts.

Contact:

https://mapsignals.com/contact/

United Therapeutics Attracts Big Money

And the biotech firm could rise even more due to a recent regulatory approval and healthy profits. But another likely reason is Big Money lifting the stock.

Big Money Back for United Therapeutics

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And United Therapeutics has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, check out how the last few weeks have seen Big Money activity. The green bar signals big trading volumes as the stock ramped in price:

Graphical user interface, chart, histogram Description automatically generated

Source: www.mapsignals.com

In the last year, the stock attracted a new Big Money buy signal, after receiving them regularly for years. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out technical action grabbing my attention:

Outperformance is important for leading stocks.

United Therapeutics Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, United Therapeutics has a strong profit margin and is attractively valued. Take a look:

  • Profit margin (+28.2%)
  • Forward price-to-earnings ratio (+12.9x)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, UTHR has been a top-rated stock at my research firm, MAPsignals, for years. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

UTHR has a lot of qualities that are attracting Big Money. It’s made the Top 20 report 53 times since 2004, with its first appearance on 05/03/2004…and gaining 1,758.7% since. Big Money was all over the shares years ago and it’s recently come back in; the blue bars below show when United Therapeutics was a top pick:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

It’s been a top stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if UTHR makes additional appearances in the years to come. Let’s tie this all together.

United Therapeutics Price Prediction

The United Therapeutics rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no positions in UTHR at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

Ely Lilly Brings in Big Money

And the drug manufacturer could jump more due to solid financial results and a bright future. But another likely reason is Big Money lifting the stock.

Big Money Loves Lilly

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And Lilly has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, have a look at all the Big Money signals LLY has made the last year.

The last few weeks have seen Big Money activity too. Each green bar signals big trading volumes as the stock ramped in price:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

In the last year, the stock attracted 16 Big Money buy signals. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out technical action grabbing my attention:

Outperformance is important for leading stocks.

Lilly Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, Lilly has been growing earnings well and sports a healthy profit margin. Take a look:

  • 3-year EPS growth rate (+28.6%)
  • Profit margin (+19.7%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, LLY has been a top-rated stock at my research firm, MAPsignals, for years. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

LLY has a lot of qualities that are attracting Big Money. It’s made the Top 20 report 83 times since 1990, with its first appearance on 01/08/1990…and gaining 4,794.5% since. The blue bars below show when Lilly was a top pick:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

It’s been a top stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if LLY makes additional appearances in the years to come. Let’s tie this all together.

Lilly Price Prediction

The Lilly rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside, and it pays a current dividend of more than 1.2%. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no positions in LLY at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

Halozyme Delivers for Big Money

And the biopharmaceutical company could jump even more due to proprietary drug delivery technology and strong forward guidance. But another likely reason is Big Money lifting the stock.

Big Money Likes Halozyme

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And Halozyme has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, have a look at all the Big Money signals HALO has made this year.

The last few weeks have seen Big Money activity too. Each green bar signals big trading volumes as the stock ramped in price:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

In the last year, the stock attracted seven Big Money buy signals. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out technical action grabbing my attention:

Outperformance is important for leading stocks.

Halozyme Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, Halozyme has been growing earnings at a big rate and is hugely profitable. Take a look:

  • 3-year sales growth rate (+43.8%)
  • Profit margin (+90.8%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, HALO has been a top-rated stock at my research firm, MAPsignals. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

HALO has a lot of qualities that are attracting Big Money. It’s made the Top 20 report five times since 2016, with its first appearance on 04/28/2020…and gaining 96.3% since. The blue bars below show when Halozyme was a top pick:

Chart, histogram Description automatically generated

Source: www.mapsignals.com

It’s been a top stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if HALO makes additional appearances in the years to come. Let’s tie this all together.

Halozyme Price Prediction

The Halozyme rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no positions in HALO at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

Merck Brings in Big Money

And the pharmaceutical company could rise even more due to strong sales growth and a healthy dividend. But another likely reason is Big Money lifting the stock.

Big Money Loves Merck

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And Merck has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, have a look at all the Big Money signals MRK has made the last year.

The last few weeks have seen Big Money activity too. Each green bar signals big trading volumes as the stock ramped in price:

Source: www.mapsignals.com

In the last year, the stock attracted 17 Big Money buy signals. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out technical action grabbing my attention:

Outperformance is important for leading stocks.

Merck Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, Merck has been growing sales and earnings at big clips. Take a look:

  • 1-year sales growth rate (+17.7%)
  • 3-year EPS growth rate (+40.6%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, MRK has been a top-rated stock at my research firm, MAPsignals, for years. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

MRK has a lot of qualities that are attracting Big Money. It’s made the Top 20 report 116 times since 1990, with its first appearance on 01/15/1990…and gaining 2,178.8% since. The blue bars below show when Merck was a top pick:

Source: www.mapsignals.com

It’s been a top stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if MRK makes additional appearances in the years to come. Let’s tie this all together.

Merck Price Prediction

The Merck rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside, and it pays a nearly 3.0% current dividend. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds long positions in MRK in personal and managed accounts at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

Regeneron Brings in the Big Money

And the drugmaker’s stock could lift even more due to its popular eczema medication and a healthy pipeline of new treatments. But another likely reason is Big Money lifting the stock.

Big Money Likes Regeneron

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And Regeneron has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, have a look at all the Big Money signals REGN has made the last year.

The last few months have seen Big Money activity too. Each green bar signals big trading volumes as the stock ramped in price:

Source: www.mapsignals.com

In the last year, the stock attracted 30 Big Money buy signals. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out technical action grabbing my attention:

Outperformance is important for leading stocks.

Regeneron Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, Regeneron has been growing sales and earnings at double-digit rates. Take a look:

  • 3-year sales growth rate (+38.1%)
  • 3-year EPS growth rate (+62.7%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, REGN has been a top-rated stock at my research firm, MAPsignals, for years. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

REGN has a lot of qualities that are attracting Big Money. It’s made the Top 20 report 49 times since 2012, with its first appearance on 10/02/2012…and gaining 334.3% since. The blue bars below show when Regeneron was a top pick:

Source: www.mapsignals.com

It’s been a top stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if REGN makes additional appearances in the years to come. Let’s tie this all together.

Regeneron Price Prediction

The Regeneron rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no positions in REGN at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

 

McKesson Brings in the Big Money

And the healthcare services firm could rise even more due to strong demand and growth prospects. But another likely reason is Big Money lifting the stock.

Big Money Drawn to McKesson

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And McKesson has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been consistent in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, have a look at all the Big Money signals MCK has made the last year.

The last few weeks have seen Big Money activity too. Each green bar signals big trading volumes as the stock ramped in price:

Source: www.mapsignals.com

In the last year, the stock attracted 27 Big Money buy signals. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out technical action grabbing my attention:

Outperformance is important for leading stocks.

McKesson Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, McKesson has been growing sales and earnings at big clips. Take a look:

  • 1-year sales growth rate (+10.8%)
  • 3-year EPS growth rate (+1,048.8%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, MCK has been a top-rated stock at my research firm, MAPsignals, for years. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

MCK has a lot of qualities that are attracting Big Money. It’s made the Top 20 report 18 times since 2000, with its first appearance on 09/18/2000…and gaining 1,036.4% since. The blue bars below show when McKesson was a top pick:

Source: www.mapsignals.com

It’s been a top stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if MCK makes additional appearances in the years to come. Let’s tie this all together.

McKesson Price Prediction

The McKesson rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside, plus it pays a current dividend of nearly 0.6%. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no positions in MCK at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/

Amphastar Feels the Big Money Love

And the specialty drug manufacturer could rise even more due to strong sales and new regulatory approvals. But another likely reason is Big Money lifting the stock.

Big Money Starts to Like Amphastar

So, what’s Big Money? Said simply, that’s when a stock goes up in price alongside chunky volumes. It’s indicative of institutions betting on the shares.

Smart money managers are always looking for the next hot stock. And Amphastar has many fundamental qualities that are attractive.

This sets up well for the stock going forward. But how the shares have been trading points to more upside. As I’ll show you, the Big Money has been taking interest in the shares.

You see, fund managers are always looking to bet on the next outlier stocks…the best in class. They spend countless hours sizing up companies, reading reports, speaking to analysts…you name it. When they find a company firing on all cylinders, they pounce in a big way.

That’s why I’ve learned how critical it is to gauge Big Money demand for shares. To show you what I mean, have a look at the Big Money interest in AMPH. The green bar signals big trading volume as the stock ramped up in price:

Source: www.mapsignals.com

In the last year, the stock received its first Big Money buy signal since 2016. Generally speaking, recent green bars could mean more upside is ahead.

Now, let’s check out technical action grabbing my attention:

Outperformance is important for leading stocks.

Amphastar Fundamental Analysis

Next, it’s a good idea to check under the hood. Meaning, I want to make sure the fundamental story is strong too. As you can see, Amphastar has been growing and is profitable. Take a look:

  • 1-year sales growth rate (+25.1%)
  • 3-year EPS growth rate (+2,082.8%)
  • Profit margin (+14.2%)

Source: FactSet

Marrying great fundamentals with technically superior stocks is a winning recipe over the long-term.

In fact, AMPH has recently become a top-rated stock at my research firm, MAPsignals. That means the stock has buy pressure, strong technicals, and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

AMPH has a lot of qualities that are attracting Big Money. It made this list for the first time recently on 04/19/2022, losing 16.2% since. But I wouldn’t be surprised to see it grow more in the years ahead. The blue bar below shows when Amphastar was a top pick:

Source: www.mapsignals.com

It’s been a hot stock in the health care sector according to the MAPsignals process. I wouldn’t be surprised if AMPH makes additional appearances in the years to come. Let’s tie this all together.

Amphastar Price Prediction

The Amphastar rally could have further to go. Big Money buying in the shares is signaling to take notice. Shares could be positioned for further upside. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a growth-oriented portfolio.

Disclosure: the author holds no positions in AMPH at the time of publication.

Learn more about the MAPsignals process here.

Contact

https://mapsignals.com/contact/